| Previous close | 19.09 |
| Open | 19.08 |
| Bid | 18.97 x 1214500 |
| Ask | 19.30 x 938700 |
| Day's range | 18.54 - 19.42 |
| 52-week range | 10.02 - 25.95 |
| Volume | |
| Avg. volume | 501,901 |
| Market cap | 2.481B |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | 15.88 |
| EPS (TTM) | 1.20 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.64 |
Simply Wall St.Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?
Most readers would already be aware that Neuren Pharmaceuticals' (ASX:NEU) stock increased significantly by 22% over...
- Simply Wall St.
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% Undervalued
Key Insights The projected fair value for Neuren Pharmaceuticals is AU$43.02 based on 2 Stage Free Cash Flow to Equity...
PR NewswireNeuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme
© 2024 Yahoo. All rights reserved.